The management of prostate cancer is undergoing rapid changes in all disease settings. Novel imaging tools for diagnosis have been introduced, and the treatment of high-risk localized, locally advanced and metastatic disease has changed considerably in recent years. From clinical and health-economic perspectives, a rational and optimal use of the available options is of the utmost importance. While international guidelines list relevant pivotal trials and give recommendations for a variety of clinical scenarios, there is much room for interpretation, and several important questions remain highly debated. The goal of developing a national consensus on the use of these novel diagnostic and therapeutic strategies in order to improve disease management and eventually patient outcomes has prompted a Swiss consensus meeting. Experts from several specialties, including urology, medical oncology, radiation oncology, pathology and nuclear medicine, discussed and voted on questions of the current most important areas of uncertainty, including the staging and treatment of high-risk localized disease, treatment of metastatic hormone-sensitive prostate cancer (mHSPC) and use of new options to treat metastatic castration-resistant prostate cancer (mCRPC).
Swiss medical weekly. 2023 Aug 15*** epublish ***
Arnoud J Templeton, Aurelius Omlin, Dominik Berthold, Jörg Beyer, Irene A Burger, Daniel Eberli, Daniel Engeler, Christian Fankhauser, Stefanie Fischer, Silke Gillessen, Guillaume Nicolas, Stephanie Kroeze, Anja Lorch, Michael Müntener, Alexandros Papachristofilou, Niklaus Schaefer, Daniel Seiler, Frank Stenner, Petros Tsantoulis, Tatjana Vlajnic, Thomas Zilli, Daniel Zwahlen, Richard Cathomas
Medical Oncology, St. Claraspital, Basel, Switzerland / St. Clara Research Ltd., Basel, Switzerland., Onkozentrum Zurich, University of Zurich., Medical Oncology, CHUV Lausanne, Vaud, Switzerland., Medical Oncology, Inselspital, Universitätsspital, Bern, Switzerland., Department of Nuclear Medicine, Kantonsspital Baden, Baden, Switzerland., Department of Urology, Universitätsspital Zürich, Zurich, Switzerland., Department of Urology, Kantonsspital St. Gallen, St. Gallen, Switzerland., Department of Urology, Luzerner Kantonsspital, Luzern, Switzerland., Department of Medical Oncology and Hematology, Kantonsspital St. Gallen, St. Gallen, Switzerland., Medical Oncology, Ente Ospedaliero Cantonale (EOC), Bellinzona, Switzerland., Department of Nuclear Medicine, Universitätsspital Basel, Basel, Switzerland., Department of Radio-Oncology, Kantonsspital Aarau, Aarau, Switzerland., Medical Oncology and Hematology, Universitätsspital Zürich, Zurich, Switzerland., Department of Urology, Stadtspital Zürich Triemli, Zurich, Switzerland., Department of Radio-Oncology, Universitätsspital Basel, Basel, Switzerland., Department of Visceral Surgery, CHUV, Lausanne, Vaud, Switzerland., Department of Urology, Rotes Schloss Zürich, Zurich, Switzerland., Medical Oncology and Hematology, Universitätsspital Basel, Basel, Switzerland., Medical Oncology and Hematology, Université de Genève (HUG), Geneva, Switzerland., Institute of Pathology, Kantonsspital Graubünden, Chur, Switzerland., Department of Radio-Oncology, Ente Ospedaliero Cantonale (EOC), Bellinzona, Switzerland., Department of Radio-Oncology, Kantonsspital Winterthur, Winterthur, Switzerland., Division of Oncology/Hematology, Kantonsspital Graubünden, Chur, Switzerland.